The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer
Medical experts analyze the impact of CDK4/6 inhibitors in early-stage HR+/Her2- breast cancer patients, and how recent clinical trial data translates to the real-world clinical application of these agents.
EP: 1.HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification
EP: 2.NCCN Guidelines vs Real-World Practice: Risk Stratifying HR+/HER2- Early Breast Cancer
EP: 3.5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer
Now Viewing
EP: 4.The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer
EP: 5.AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes
EP: 6.Shared Decision Making and Multidisciplinary Collaboration in the Evolving HR+/HER2- Early-Stage Breast Cancer Landscape
This OncLive Insights video series was supported by an independent sponsorship from Eli Lilly. Eli Lilly had no input into the content or development of this OncLive Insights video series. Content was independently developed and published by OncLive.
Related Videos
Related Content
